-
2241
Regulatory Immunotherapy in Bone Marrow Transplantation
Published 2011-01-01“…Every year individuals receive hematopoietic stem cell transplantation (HSCT) to eradicate malignant and nonmalignant disease. …”
Get full text
Article -
2242
Protocol to image, segment, and quantify cortical contractions in maturing mouse oocytes
Published 2025-03-01Get full text
Article -
2243
-
2244
Interleukin 15‐Presenting Nanovesicles with Doxorubicin‐Loaded Ferritin Cores for Cancer Immunochemotherapy
Published 2025-01-01Get full text
Article -
2245
Reduction of elevated Gli3 does not alter the progression of autosomal recessive polycystic kidney disease
Published 2025-01-01Get full text
Article -
2246
Classification of distinct tendinopathy subtypes for precision therapeutics
Published 2024-11-01Get full text
Article -
2247
Understanding the multifaceted nature of peptide hydrogels in biomedical research
Published 2024-03-01“…In this review, we will present the recent advancements that have occurred in the field of peptide-based hydrogels concerning its biomedical applications especially delivery of targeted delivery, wound healing, tissue engineering, stem cell therapy, etc.…”
Get full text
Article -
2248
Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients
Published 2025-01-01“…Acute myelogenous leukemia(AML) is a life-threatening hematologic malignancy that predominantly affects the elderly.Currently, chemotherapy and hematopoietic stem cell transplantation are the primary treatment modalities for AML, though their clinical application is limited in older patients.Recent years have seen the development of novel molecular targeted therapies, such as isocitrate dehydrogenase 1/2 (IDH1/2) and Feline macrophage stimulator-like tyrosine kinase 3 (FLT3) inhibitors, as well as individualized approaches like chimeric antigen receptor T-cell (CAR-T) therapy.However, due to patient heterogeneity and drug resistance, treatment outcomes for elderly AML remain unsatisfactory, underscoring the need for more precise and safer individualized treatment strategies.The combination of chemotherapy with novel targeted or immunotherapies shows promise as a future treatment direction.This research reviews the latest advances in the treatment of elderly AML, with a focus on achieving more individualized and safer therapeutic approaches.…”
Get full text
Article -
2249
The Urodele Limb Regeneration Blastema: The Cell Potential
Published 2010-01-01“…Other cells from the dermis act as multipotent stem cells that replenish dermal fibroblasts and differentiate into cartilage. …”
Get full text
Article -
2250
Florid Proliferation of Hyalinized Vessels in a Spermatic Cord STAT6 Positive Solitary Fibrous Tumor and Its Potential Clinical Implications
Published 2018-01-01“…We also summarize our current understanding of the structural and molecular features that make up SFTs and discuss how these features may help us better understand the pathophysiology of pluripotent mesenchymal stem cell differentiation.…”
Get full text
Article -
2251
The Role of Bacteria and Pattern Recognition Receptors in GvHD
Published 2010-01-01“…Graft-versus-Host Disease (GvHD) is the most serious complication of allogeneic stem cell transplantation (SCT) and results from an activation of donor lymphocytes by recipient antigen-presenting cells (APCs). …”
Get full text
Article -
2252
Tracheobronchial Manifestations of Aspergillus Infections
Published 2011-01-01“…Thus, invasive or potentially invasive Aspergillus airway diseases are discussed separately in three groups of patients: (1) lung transplant recipients, (2) highly immunocompromised patients with hematologic malignancies and/or patients undergoing hematopoietic stem cell transplantation, and (3) the remaining, less severely immunocompromised patients or even immunocompetent subjects.…”
Get full text
Article -
2253
Small-Sized Clone of T Cells in Multiple Myeloma Patient after Auto-SCT: T-LGL Leukemia Type or Clonal T-Cell Aberration?
Published 2013-01-01“…Second cancers and particularly postransplant lymphoproliferative disorders (PTLDs) are extremely rare in patients undergoing autologous peripheral blood stem cell transplantation (auto-SCT). We report the case of clonally rearranged T-cell expansion which occurred after auto-SCT for Multiple Myeloma (MM). …”
Get full text
Article -
2254
Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies
Published 2025-01-01“…Abstract The established protocol for the management of acute myeloid leukemia (AML) has traditionally involved the administration of induction chemotherapy, followed by consolidation chemotherapy, and subsequent allogeneic stem cell transplantation for eligible patients. However, the prognosis for individuals with relapsed and refractory AML remains unfavorable. …”
Get full text
Article -
2255
Plasma Cell Leukemia: A Review of 3 Cases Managed in Kenya
Published 2021-01-01“…Treatment with novel agents followed by autologous stem cell transplant in those who are transplant eligible leads to better outcomes.…”
Get full text
Article -
2256
Long-Term Use of Ruxolitinib in an AML Patient with Posttransplant Steroid Refractory GVHD
Published 2020-01-01“…We present a case of a 32-year-old male on ruxolitinib with GVHD status postmatched unrelated donor stem cell transplant (MUD SCT) for acute myeloid leukemia (AML) with FLT3 mutation currently on ruxolitinib for 5 years who is not able to tolerate reduction in dosage due to flare-ups. …”
Get full text
Article -
2257
Late Onset and Protracted Course of Steroid Refractory Chronic Graft-versus-Host Disease
Published 2015-01-01“…Chronic graft-versus-host disease (cGVHD) is one of the most important causes of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (aHSCT). Occurring in 30% to 70% of patients, cGVHD has a median time to onset of 4 to 6 months and most cases present within 2 years after aHSCT. …”
Get full text
Article -
2258
-
2259
Cavernous Nerve Injury Resulted Erectile Dysfunction and Regeneration
Published 2021-01-01“…In addition, such as neuromodulatory proteins, proimmune ligands, gene therapy, stem cell therapy, and the current cutting-edge low-energy shock wave therapy have shown advantages in basic research and limited clinical studies. …”
Get full text
Article -
2260
Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas
Published 2012-01-01“…Alternative chemoimmunotherapy regimens are often used as salvage strategy and stem cell transplant remains an option for selected patients. …”
Get full text
Article